FDA Approved: EXONDYS 51 — Supplemental Application (Sarepta Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Exondys 51 (eteplirsen) submitted by Sarepta Therapeutics, expanding its regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EXONDYS 51 (eteplirsen)

Snippet

SUPPL AP for EXONDYS 51 (ETEPLIRSEN)